2024
The Association of Anemia With Survival Among People With HIV Following Antiretroviral Initiation in the NA-ACCORD 2007–2016
Lang R, Coburn S, Gill M, Grossman J, Gebo K, Horberg M, Mayor A, Justice A, Bosch R, Silverberg M, Rabkin C, Sterling T, Thorne J, Moore R, Althoff K, AIDS F. The Association of Anemia With Survival Among People With HIV Following Antiretroviral Initiation in the NA-ACCORD 2007–2016. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 97: 334-343. PMID: 39118208, PMCID: PMC11732725, DOI: 10.1097/qai.0000000000003502.Peer-Reviewed Original ResearchConceptsMortality riskAntiretroviral therapyNA-ACCORDSevere anemiaMacrocytic anemiaMicrocytic anemiaInitiation of antiretroviral therapyMortality hazard ratioWorld Health Organization criteriaHIV clinical markersDecreased mortality riskIncreased mortality riskMedian hemoglobin levelHemoglobin measurementsAssociation of anemiaPredictors of mortalityTime-to-event analysisAntiretroviral initiationHazard ratioOrganization criteriaPredictive markerNormocytic anemiaModerate anemiaHemoglobin levelsMild anemia
2023
Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study
Grinblatt D, Roboz G, Pollyea D, Sekeres M, Scott B, Seiter K, Zeidan A, Patel J, Garcia-Manero G, Komrokji R, Savona M, Degutis I, Kiselev P, Yu E, Heydendael W, Qiu Y, Vergara S, McBride A, Erba H. Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study. Blood 2023, 142: 593. DOI: 10.1182/blood-2023-189963.Peer-Reviewed Original ResearchAcute myeloid leukemiaYears of ageMedian overall survivalProportion of patientsOverall survivalRate of transplantGroup 2Group 1Molecular testingTreatment patternsAML cohortMedian (95% CI) OSMyeloid diseasesReal-world clinical practiceWorld Health Organization criteriaIntensive chemotherapy regimensLow-intensity chemotherapyObservational cohort studyOutcomes of patientsFirst-line treatmentKaplan-Meier methodProspective observational studyYear of diagnosisDate of diagnosisTreatment of patientsPredicting Delayed Shock in Multisystem Inflammatory Disease in Children
Levine D, Uy V, Krief W, Bornstein C, Daswani D, Patel D, Kriegel M, Jamal N, Patel K, Liang T, Arroyo A, Strother C, Lim C, Langhan M, Hassoun A, Chamdawala H, Kaplan C, Waseem M, Tay E, Mortel D, Sivitz A, Kelly C, Lee H, Qiu Y, Gorelik M, Platt S, Dayan P. Predicting Delayed Shock in Multisystem Inflammatory Disease in Children. Pediatric Emergency Care 2023, 39: 555-561. PMID: 36811547, DOI: 10.1097/pec.0000000000002914.Peer-Reviewed Original ResearchConceptsC-reactive proteinMultisystem inflammatory diseaseLymphocyte percentLower riskIndependent predictorsInflammatory diseasesSerum C-reactive proteinRetrospective cross-sectional studyWorld Health Organization criteriaRisk of progressionCross-sectional studyLevel of careCRP levelsPediatric EDOrganization criteriaLaboratory factorsMAIN OUTCOMEPatientsRiskChildrenDiseaseDifferentiated childrenPlateletsPredictorsTri-state area
2022
Body mass index from the RE-LY trial: further evidence of the obesity paradox
Jacobs M, Ezekowitz M, Nagarakanti R, Eikelboom J, Khan O, Reiss J, Liu H, McAndrew T, Francese D, Arce J, Brueckmann M, Connolly S, Yusuf S. Body mass index from the RE-LY trial: further evidence of the obesity paradox. European Heart Journal 2022, 43: ehac544.629. DOI: 10.1093/eurheartj/ehac544.629.Peer-Reviewed Original ResearchBody mass indexDirect oral anticoagulantsRE-LY trialObesity paradoxMajor bleedingIntracranial hemorrhageSystemic embolismIschemic strokeDrug assignmentMass indexResults Body mass indexHigher Body Mass IndexWorld Health Organization criteriaCox proportional hazards modelIntracranial hemorrhage rateIschemic stroke rateRates of diabetesProportional hazards modelContinuous variablesLower ratesPrior strokeOral anticoagulantsRE-LYBaseline characteristicsCreatinine clearanceEarly pregnancy hyperglycaemia as a significant predictor of large for gestational age neonates
Jayasinghe IU, Koralegedara IS, Agampodi SB. Early pregnancy hyperglycaemia as a significant predictor of large for gestational age neonates. Acta Diabetologica 2022, 59: 535-543. PMID: 34973071, PMCID: PMC8917036, DOI: 10.1007/s00592-021-01828-1.Peer-Reviewed Original ResearchConceptsGestational diabetes mellitusGestational age neonatesLGA neonatesAge neonatesGestational ageFirst trimesterPrevalence of GDMWorld Health Organization criteriaDelivery gestational ageNeonatal birth weightPregnancy Study GroupsBirth weight centileMedian gestational ageProspective cohort studyAttributable risk percentageHigh-risk populationUndiagnosed DMCohort studyCumulative incidenceDiabetes mellitusWeight centileEarly pregnancyPregnant womenMean ageOrganization criteria
2021
Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation
Alasfar S, Hall IE, Mansour SG, Jia Y, Thiessen-Philbrook HR, Weng FL, Singh P, Schröppel B, Muthukumar T, Mohan S, Malik RF, Harhay MN, Doshi MD, Akalin E, Bromberg JS, Brennan DC, Reese PP, Parikh CR. Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation. BMC Nephrology 2021, 22: 26. PMID: 33435916, PMCID: PMC7802150, DOI: 10.1186/s12882-021-02231-2.Peer-Reviewed Original ResearchConceptsKidney Donor Profile IndexRAAS inhibitorsRisk factorsLower kidney donor profile indexDeceased donor kidney transplantationWorld Health Organization criteriaHigh kidney donor profile indexCurrent transplant practiceHigh-quality kidneysPost-transplant erythrocytosisDonor kidney transplantationMajority of patientsLarge recent cohortPolycystic kidney diseaseRisk of PTEsKidney recipientsTransplant erythrocytosisCerebrovascular eventsKidney transplantationPTE patientsConclusionsThe incidenceGraft failureContemporary incidenceDeceased donorsKidney disease
2020
Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions
Chen PH, Bossuyt V, Reisenbichler E. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Human Pathology 2020, 108: 68-75. PMID: 33245988, DOI: 10.1016/j.humpath.2020.11.009.Peer-Reviewed Original ResearchConceptsMalignant phyllodes tumorPhyllodes tumorBenign tumorsLymphoid enhancer-binding factor 1Fibroepithelial lesionsTissue microarrayEnhancer-binding factor 1LEF-1 expressionMalignant tumorsBorderline/malignant phyllodes tumorsΒ-cateninStromal componentsNuclear expressionWorld Health Organization criteriaMetastatic phyllodes tumorWnt/β-catenin pathway activationAlternative treatment optionBorderline phyllodes tumorWnt/β-catenin pathwayFactor 1Β-catenin pathway activationE-cadherin immunohistochemistryWnt/β-catenin signalingΒ-catenin pathwayNuclear β-catenin staining
2019
Anemia at Discharge From the PICU: A Bicenter Descriptive Study.
Demaret P, Valla FV, Behal H, Mimouni Y, Baudelet JB, Karam O, Recher M, Duhamel A, Tucci M, Javouhey E, Leteurtre S. Anemia at Discharge From the PICU: A Bicenter Descriptive Study. Pediatric Critical Care Medicine 2019, 20: e400-e409. PMID: 31246740, DOI: 10.1097/pcc.0000000000002015.Peer-Reviewed Original ResearchConceptsPediatric critical illnessPICU admissionPICU dischargeRisk of anemiaCritical illnessRisk markersHigher C-reactive protein levelsInotropic/vasopressor supportC-reactive protein levelsWorld Health Organization criteriaMedian hemoglobin levelRetrospective cohort studyElectronic medical recordsVasopressor supportPlasma transfusionCohort studyCreatinine levelsMultivariate adjustmentAnemic childrenHemoglobin levelsMechanical ventilationAnemia statusOrganization criteriaMedical recordsIll children
2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model
Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European Radiology 2017, 27: 4995-5005. PMID: 28677067, PMCID: PMC5675796, DOI: 10.1007/s00330-017-4856-2.Peer-Reviewed Original ResearchConceptsMultivariate Cox proportional hazards modelConventional transarterial chemoembolisationMedian overall survivalPropensity score analysisHepatic progression-free survivalDrug-eluting beads TACEYttrium-90 radioembolisationProgression-free survivalDEB-TACELiver metastasesOverall survivalBeads TACENeuroendocrine tumor liver metastasesWorld Health Organization criteriaCox proportional hazards modelIntra-arterial therapyMethodsThis retrospective analysisResponse Evaluation CriteriaScore analysisSignificant survival benefitLonger overall survivalGastroenteropancreatic neuroendocrine tumorsLog-rank testEntire study populationProportional hazards model
2016
Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications
Lee L, Yantiss R, Sadot E, Ren B, Calvacanti M, Hechtman J, Ivelja S, Huynh B, Xue Y, Shitilbans T, Guend H, Stadler Z, Weiser M, Vakiani E, Gönen M, Klimstra D, Shia J. Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology 2016, 62: 74-82. PMID: 28034727, PMCID: PMC5392420, DOI: 10.1016/j.humpath.2016.12.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyCarcinoma, MedullaryCell DifferentiationColorectal NeoplasmsDNA Mismatch RepairDNA Repair EnzymesFemaleHumansImmunohistochemistryMaleMiddle AgedObserver VariationPredictive Value of TestsPrognosisReproducibility of ResultsTerminology as TopicYoung AdultConceptsMedullary carcinomaDiagnosis of medullary carcinomaGroup 3World Health Organization criteriaDiagnose medullary carcinomaSpectrum of histologyHistological subtypesMedullary tumorsMismatch repair deficiencyPrognostic relevanceMismatch repair protein deficiencyOrganization criteriaImproved survivalImprove prognosisClinicopathological implicationsGastrointestinal pathologistsInterobserver agreementMorphologic spectrumColorectal adenocarcinomaInterobserver variabilityGroup 1CarcinomaMolecular pathogenesisWorld Health OrganizationProtein deficiencyEstablishment of a hospital-acquired infection surveillance system in a teaching hospital in Rwanda
Lukas S, Hogan U, Muhirwa V, Davis C, Nyiligira J, Ogbuagu O, Wong R. Establishment of a hospital-acquired infection surveillance system in a teaching hospital in Rwanda. International Journal Of Infection Control 2016, 12 DOI: 10.3396/ijic.v12i3.018.16.Peer-Reviewed Original ResearchIntensive care unitHAI ratesTeaching hospitalHAI surveillanceNeonatal intensive care unitWorld Health Organization criteriaLonger hospital lengthInfections Surveillance SystemRisk of HAINaso-gastric tubeInfection prevention effortsResource-limited countriesHAI surveillance systemLow-resource settingsHigher HAI ratesSurveillance systemHospital lengthCare unitOrganization criteriaChest drainInfection surveillanceUrinary catheterMulti-disciplinary teamInpatient unitExternal fixatorCost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States
Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP. Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. American Journal Of Epidemiology 2016, 183: 1159-1170. PMID: 27188951, PMCID: PMC4908210, DOI: 10.1093/aje/kwv347.Peer-Reviewed Original ResearchConceptsMaternal vaccinationAdult vaccinationWorld Health Organization criteriaPrimary vaccination seriesVaccination of mothersRecent epidemiologic evidenceAge-stratified transmission modelMaternal antibody transferPertussis vaccinationPostpartum vaccinationVaccination seriesAntibody transferEpidemiologic evidenceOrganization criteriaPertussis incidenceDisease burdenCurrent recommendationsSevere casesVaccinationInfantsPregnancyDirect protectionUS mothersMothersPertussisImpact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1877-1883. PMID: 27131611, DOI: 10.1016/j.amjcard.2016.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug Therapy, CombinationDrug-Eluting StentsEuropeFemaleHemorrhageHumansIncidenceMaleMiddle AgedMyocardial IschemiaPercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesRegistriesRisk AssessmentRisk FactorsSurvival RateTiclopidineUnited StatesConceptsHigh platelet reactivityDrug-Eluting Stents studyMajor adverse cardiac eventsAdverse cardiac eventsDual antiplatelet therapyPlatelet reactivityAntiplatelet therapyMajor bleedingCause mortalityCardiac eventsMultivariate adjustmentStent studiesWorld Health Organization criteriaImpact of anemiaPresence of anemiaPercutaneous coronary interventionDrug-eluting stentsIschemic riskBleeding riskClinical confoundersCoronary interventionAnemic patientsClinical outcomesHemoglobin levelsStudy cohortASSOCIATION OF HOUSEHOLD FOOD INSECURITY, NUTRITIONAL STATUS, ENERGY AND NUTRIENTS INTAKE IN FEMALE‐HEADED HOUSEHOLDS FROM CULIACAN, SINALOA, MEXICO
Ochoa D, Osuna‐Ramirez I, Pérez‐Escamilla R, Plazas‐Guerrero C, De Jesús Vergara‐Jiménez M. ASSOCIATION OF HOUSEHOLD FOOD INSECURITY, NUTRITIONAL STATUS, ENERGY AND NUTRIENTS INTAKE IN FEMALE‐HEADED HOUSEHOLDS FROM CULIACAN, SINALOA, MEXICO. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.899.6.Peer-Reviewed Original ResearchNutritional statusFood insecurity levelsWorld Health Organization criteriaCaribbean Food Security ScaleFood frequency questionnaireRelated chronic diseasesFrequency questionnaireNormal weightWaist circumferenceDietary recallsInadequate intakeOrganization criteriaRisk factorsChronic diseasesCardiovascular diseaseFood Security ScaleHousehold food insecurityFood insecurityMetabolic diseasesEnergy intakeNutritional deficienciesMacronutrient consumptionNutrient intakeBalanced dietGood health
2015
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G, Pond G, Templeton A, Petrylak D, Tombal B, Rosenthal M, Tannock I. Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2015, 33: 186-186. DOI: 10.1200/jco.2015.33.7_suppl.186.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProgressive diseaseOverall survivalPartial responseAssociation of changesMeasurable diseaseStable diseaseHazard ratioLandmark analysisDay 90Castration-resistant prostate cancerWorld Health Organization criteriaMeasurable disease responseUnconfirmed partial responseECOG performance statusMedian overall survivalNeutrophil-lymphocyte ratioPhase II trialResponse Evaluation CriteriaProportional hazards regressionAccrual of patientsType of progressionMeasurable lesionsRECIST 1.0VENICE trial
2011
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease
Vanasse GJ, Jeong JY, Tate J, Bathulapalli H, Anderson D, Steen H, Fleming M, Mattocks K, Telenti A, Fellay J, Justice AC, Berliner N. A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood 2011, 118: 5401-5408. PMID: 21926355, PMCID: PMC3217345, DOI: 10.1182/blood-2011-06-362194.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCombined antiretroviral therapyPrevalence of anemiaHIV diseaseSingle nucleotide polymorphismsModern combined antiretroviral therapyWorld Health Organization criteriaAging Cohort StudyA Single Nucleotide PolymorphismGene single nucleotide polymorphismsLeptin gene promoterHIV subjectsAntiretroviral therapyCohort studyHIV statusOrganization criteriaClinical dataIndependent cohortAnemiaHIVPatientsLeptin genePrevalenceDiseaseCandidate gene approachSocio-economic status, urbanization, and cardiometabolic risk factors among middle-aged adults in Tanzania.
Njelekela MA, Liu E, Mpembeni R, Muhihi A, Mligiliche N, Spiegelman D, Finkelstein JL, Fawzi WW, Willett WC, Mtabaji J. Socio-economic status, urbanization, and cardiometabolic risk factors among middle-aged adults in Tanzania. East African Journal Of Public Health 2011, 8: 216-23. PMID: 23120960.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood PressureBody Mass IndexCardiovascular DiseasesCross-Sectional StudiesDietExerciseFemaleHealth BehaviorHumansLife StyleLipidsLogistic ModelsMaleMetabolic SyndromeMiddle AgedObesityResidence CharacteristicsRisk FactorsSocioeconomic FactorsSurveys and QuestionnairesTanzaniaUrban HealthUrbanizationWaist CircumferenceConceptsCardiometabolic risk factorsPoorer lipid profileHigher socioeconomic statusRisk factorsLipid profileSocioeconomic statusUrban residenceCardio-metabolic risk factorsWorld Health Organization criteriaHigher total cholesterolHigh waist circumferenceRisk of obesityHealth screening strategiesMiddle-aged adultsMetabolic syndromeTotal cholesterolWaist circumferenceLDL cholesterolHigher BMIPrimary preventionLower triglyceridesOrganization criteriaDietary factorsCardiovascular diseaseGlucose levels
2009
Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival lossPrevalence and risk factors associated with decreased bone mineral density in patients with haemophilia
GERSTNER G, DAMIANO M, TOM A, WORMAN C, SCHULTZ W, RECHT M, STOPECK A. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009, 15: 559-565. PMID: 19187193, DOI: 10.1111/j.1365-2516.2008.01963.x.Peer-Reviewed Original ResearchConceptsDual-energy X-ray absorptiometryBone mineral densityLowest T-scoreBone lossMineral densityPrevalence of vitamin D insufficiencySerum 25-hydroxyvitamin D levelsDecreased BMDT-scoreDecreased bone mineral densityWorld Health Organization criteriaHistory of inhibitorsLower body mass indexVitamin D insufficiencyX-ray absorptiometryVitamin D supplementationPrevent bone lossHistory of HCVBody mass indexLower activity scoresJoint mobility measurementsPhysical Activity QuestionnaireLower body weightD insufficiencyHIV infection
2007
Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer
Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 2007, 13: 257-262. PMID: 17762761, DOI: 10.1097/ppo.0b013e31813c1174.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic cancerPancreatic cancerEligible patientsIrinotecan combinationPartial responseComplete responseEastern Cooperative Oncology Group performance status 0Principal grade 3/4 toxicitiesWorld Health Organization criteriaSafety of docetaxelGrade 3/4 toxicitiesObjective response ratePerformance status 0One-year survivalPhase II trialCombination of docetaxelNormal bilirubin levelsEvaluable patientsFebrile neutropeniaMeasurable diseaseStatus 0Toxic deathsUnresectable diseaseII trialRecurrent disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply